BTK Inhibitors for the Treatment of Relapsed CLL

News
Video

Seema Ali Bhat, MD, explains the SEQUOIA trial and the BTK inhibitor zanubrutinib for the frontline treatment of CLL, and Alexey Danilov, MD, PhD, describes the ASCEND trial that led to the approval of acalabrutinib for relapsed CLL.

Recent Videos
A phase 1/2 trial assessed the use of menin inhibitor DSP-5336 in patients with acute leukemia overexpressing HOXA9 and MEIS1.
A pooled analysis trial assessed the impact of acalabrutinib in patients with chronic lymphocytic leukemia across treatment lines.
Overall survival data with blinatumomab in the phase 3 E1910 study may be an “important development” in CD19-positive B-ALL.
Rahul Gosain, MD; Nitin Jain, MD; and Rohit Gosain, MD, presenting slides
Rahul Gosain, MD; Nitin Jain, MD; and Rohit Gosain, MD, presenting slides
Rahul Gosain, MD; Nitin Jain, MD; and Rohit Gosain, MD, presenting slides
Rahul Gosain, MD; Nitin Jain, MD; and Rohit Gosain, MD, presenting slides
Related Content
SLS009 is a highly selective CDK9 inhibitor that is being studied in an ongoing phase 1/2 trial for patients with hematologic malignancies.

FDA Grants SLS009 Rare Pediatric Disease Designation in Pediatric AML

Gina Mauro
July 21st 2024
Article

SLS009 is a highly selective CDK9 inhibitor that is being studied in an ongoing phase 1/2 trial for patients with hematologic malignancies.

Managing Cytokine Release Syndrome in Patients on CAR T-Cell Therapy

Managing Cytokine Release Syndrome in Patients on CAR T-Cell Therapy

Elizabeth Shpall, MD
May 29th 2019
Podcast

Ahead of the ASCO Annual Meeting, we discuss the assessment and management of cytokine release syndrome in patients with cancer with Elizabeth Shpall, MD.

Data from a phase 1/2 trial support the potential clinical activity of DSP-5336 in patients with relapsed/refractory AML harboring a KMT2A rearrangement.

DSP-5336 Earns FDA Fast Track Status in R/R KMT2A+ Acute Myeloid Leukemia

Russ Conroy
July 16th 2024
Article

Data from a phase 1/2 trial support the potential clinical activity of DSP-5336 in patients with relapsed/refractory AML harboring a KMT2A rearrangement.

Immunotherapy Approaches in AML

Immunotherapy Approaches in AML

Naval Daver, MD
January 17th 2019
Podcast

Cancer Network sat down with Dr. Naval Daver to discuss advancements and discoveries in immunotherapy for AML patients.

Investigators will assess the clinical activity, safety, and pharmacokinetics of GTB-3650 among those with CD33-expressing cancers in a phase 1 trial.

GTB-3650 Snags FDA Clearance for IND Application in CD33+ Leukemia

Gina Mauro
July 3rd 2024
Article

Investigators will assess the clinical activity, safety, and pharmacokinetics of GTB-3650 among those with CD33-expressing cancers in a phase 1 trial.

Trajectories of Change in Physical Wellbeing Reported for AML Subgroups

Trajectories of Change in Physical Wellbeing Reported for AML Subgroups

Roman Fabbricatore
June 18th 2024
Article

Four trajectories of change were identified in FACT-PWB score, with large patient groups experiencing little to no change or slight declines in PWB.